Standard antiplatelet — Competitive Intelligence Brief

Standard antiplatelet (Standard antiplatelet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antiplatelet. Area: Cardiovascular.

phase 3 antiplatelet P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Standard antiplatelet (Standard antiplatelet) — Beijing Tiantan Hospital. Standard antiplatelet drugs work by inhibiting platelet activation and aggregation, preventing blood clots from forming.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard antiplatelet TARGET	Standard antiplatelet	Beijing Tiantan Hospital	phase 3	antiplatelet	P2Y12 receptor
Beta blocker, aspirin, clopidogrel	Beta blocker, aspirin, clopidogrel	Spanish Society of Cardiology	marketed	Combination antithrombotic and antihypertensive therapy	Beta-adrenergic receptors; COX-1; P2Y12 receptor
Clopidogrel only	Clopidogrel only	Seung-Jung Park	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Aspirin and thienopyridine	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)
Clopidogrel treatment	Clopidogrel treatment	VA Office of Research and Development	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
CYP2C19 Genotype Guided DAPT	CYP2C19 Genotype Guided DAPT	Zunyi Medical College	marketed	Pharmacogenomic-guided antiplatelet therapy strategy	CYP2C19 enzyme; P2Y12 receptor (indirect)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antiplatelet class)

1. Beijing Tiantan Hospital · 1 drug in this class
2. Catholic University of the Sacred Heart · 1 drug in this class
3. Icahn School of Medicine at Mount Sinai · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. Samsung Medical Center · 1 drug in this class
6. Sheba Medical Center · 1 drug in this class
7. Sichuan Provincial People's Hospital · 1 drug in this class
8. University of Athens · 1 drug in this class